申请人:Merck Frosst Canada & Co.
公开号:US06133292A1
公开(公告)日:2000-10-17
The invention encompasses compounds of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I ##STR1## e.g. (5R)-3-(3,4-difluorophenyl)-5-ethyl-5-methyl-4-[4-(methylsulfonyl)phenyl]- 2,5-dihydro-2-furanone.
该发明涵盖了公式I的化合物,以及一种治疗COX-2介导疾病的方法,包括向需要此类治疗的患者施用公式I的化合物的非毒性治疗有效量,例如(5R)-3-(3,4-二氟苯基)-5-乙基-5-甲基-4- [4-(甲基磺酰基)苯基] -2,5-二氢呋喃酮。